Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
Cited by 64
Related Papers
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Low Physical Activity Accentuates the Effect of the <i>FTO</i> rs9939609 Polymorphism on Body Fat Accumulation
|Diabetes|2007|476
Impact of postprandial glycaemia on health and prevention of disease
|Obesity Reviews|2012|470
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
|New England Journal of Medicine|2021|469
Incretins, insulin secretion and Type 2 diabetes mellitus
|Diabetologia|2004|438